Immunologic biomarker, long-term efficacy and safety of HDM SCIT among Chinese populations

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800018602

Enrollment

Unknown

Registered

2018-09-30

Start date

2018-10-12

Completion date

Unknown

Last updated

2018-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

Control group:Symptomatic drug therapy

Active group:Standard Alutard SCIT treatment

Eligibility

Sex/Gender

All

Age

5 Years to 50 Years

Inclusion criteria

Inclusion criteria: Aged from 5 to 50 years, the inclusion & exclusion criteria is just the same as in the SmPC of Alutard SQ and the routine outpatient operation.

Exclusion criteria

Exclusion criteria: The inclusion & exclusion criteria is just the same as in the SmPC of Alutard SQ and the routine outpatient operation.

Design outcomes

Primary

Measure	Time frame
Specific IgE against 19 allergens including Der p and Der f;Der p specific IgG4 & IgG1against Der p;Der p specific IgE blocking factor;Rhinitis Symptom & Medication Score;Asthma Symptom Score;Rhinitis & Asthma QoL Score;	—

Countries

China

Contacts

Public ContactXu Rui

ENT department, The First Affiliated Hospital, Sun Yat-sen University

gzxur2708@163.com+86 13802509090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026